A new study found that the immunotherapy treatment worked against some types of cancers, allowing patients to avoid surgery ...

Aidixi plus BCG showed strong early efficacy and manageable safety in patients with high-risk, HER2-expressing ...

The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent Imfinzi as adjuvant ...

Pfizer’s sasanlimab, when used with standard of care, reduced the likelihood of disease recurrence or progression, death due ...

Patients with some gastrointestinal tumors were able to be treated with immunotherapy drugs alone and avoid surgery, ...

LAS VEGAS -- Event-free survival (EFS) in high-risk non-muscle invasive bladder cancer (NMIBC) improved significantly when patients received the PD-1 inhibitor sasanlimab in addition to bacillus ...

In a groundbreaking cancer study, researchers found that immunotherapy drugs alone can treat gastrointestinal tumours.For as ...

LAS VEGAS -- Event-free survival (EFS) in high-risk non-muscle invasive bladder cancer (NMIBC ... most commonly hepatitis (3.4%), rash (2.9%), and pancreatitis (2.0%). The study was supported ...

Thirty-five of 54 patients with tumors in places such as the colon, bladder, esophagus and stomach saw their cancer disappear ... some patients experienced mild rashes or itching, while a smaller ...

Updated findings from a phase 2 study investigating the IL-2–binding monoclonal antibody AU-007 show a manageable safety ...

Neoadjuvant PD-1 blockade with dostarlimab achieved high rates of organ preservation in patients with early-stage mismatch ...